Odd Erik Johansen

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Christoph Wanner, Silvio E. Inzucchi, John M. Lachin et al. · New England Journal of Medicine · 2016 · 3.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

David Z.I. Cherney, Bruce A. Perkins, Nima Soleymanlou et al. · Circulation · 2013 · 1.3K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk

Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen et al. · JAMA · 2018 · 1.1K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +11

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

Silvio E. Inzucchi, Bernard Zinman, David Fitchett et al. · Diabetes Care · 2017 · 747 citations

Medicine, Pharmacology, Pharmacotherapy +15